SCHEDULE: Advent International Signs NDA with Definitive Healthcare

Advent International, L.P. has entered into a confidentiality agreement with Definitive Healthcare Corp. to explore a potential transaction, including a 12-month standstill provision.

Summary

• Advent International, L.P. (Advent LP) has entered into a confidentiality agreement (NDA) with Definitive Healthcare Corp. (the Company) on September 29, 2026.
• The NDA allows Advent LP to consider, evaluate, and negotiate a potential transaction with the Company.
• Advent LP is restricted from disclosing confidential information except to approved representatives and potential funding sources.
• The agreement includes a 12-month non-solicitation provision for the Company's executive officers and a 12-month standstill provision.
• The standstill provision restricts Advent LP from certain acquisitions of securities or assets, forming groups, seeking board representation, or influencing voting without the Company's consent.
• Advent LP intends to continue engaging with the Company's Special Committee and third parties regarding a potential transaction.
• This filing is an amendment (Amendment No. 1) to a previously filed Schedule 13D.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily concerns a confidentiality agreement and standstill provisions related to a potential transaction, rather than concrete operational or financial updates.

Positives

• Advent International is actively exploring a potential transaction with Definitive Healthcare, indicating strategic interest.
• The confidentiality agreement allows for structured discussions and due diligence regarding a potential deal.
• The company is engaging with the Special Committee, suggesting a formal process is underway.

Negatives

• The filing does not provide any financial performance updates or operational improvements for Definitive Healthcare.
• The standstill agreement imposes significant restrictions on Advent International's actions for 12 months, limiting their flexibility.
• The nature of the potential transaction is not specified, leaving its potential benefits or drawbacks unclear.

Risks

• The 12-month standstill provision limits Advent International's ability to acquire more securities or assets of Definitive Healthcare, or to influence its governance.
• The non-solicitation clause restricts Advent International from hiring the Company's executive officers for 12 months.
• There is no guarantee that a definitive agreement will be reached, as the company can terminate discussions at any time.
• The confidentiality agreement restricts the use of information to the evaluation of a potential transaction, limiting broader strategic use.

Future Outlook

The filing indicates that Advent International intends to continue engaging with the Special Committee and third parties regarding a potential transaction with Definitive Healthcare. The confidentiality agreement and standstill provisions are in place for 12 months.

Management Comments

• Advent LP intends to continue to engage with the Special Committee and third parties, including Mr. Krantz, regarding a transaction with the Issuer.

Industry Context

StockSavvy.ai notes that the execution of a confidentiality agreement and the subsequent filing of a Schedule 13D amendment are common steps when a significant investor like Advent International explores a potential acquisition or strategic transaction with a company in the healthcare technology sector.

Stakeholder Impact

• Shareholders: The potential for a transaction could lead to future changes in ownership or strategic direction, impacting share value. The standstill agreement limits Advent's ability to increase its stake or influence governance in the short term.
• Management and Employees: The non-solicitation clause restricts Advent from hiring executive officers for 12 months, potentially impacting talent retention and recruitment strategies.
• Customers and Suppliers: The focus on a potential transaction may divert management attention, though day-to-day operations are expected to continue under the confidentiality agreement.

Next Steps

• Advent International will continue to engage with Definitive Healthcare's Special Committee and third parties regarding a potential transaction.
• Advent International will operate under the terms of the confidentiality and standstill agreement for the next 12 months.

Key Dates

Keywords

Confidentiality Agreement, Schedule 13D, Advent International, Definitive Healthcare, Potential Transaction, Standstill Agreement, Non-solicitation, SEC Filing